PMID- 27750215 OWN - NLM STAT- MEDLINE DCOM- 20180223 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 44 DP - 2016 Nov 1 TI - Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. PG - 72219-72228 LID - 10.18632/oncotarget.12663 [doi] AB - The prognostic value of pretreatment serum beta-2 microglobulin (B2MG) level in advanced Hodgkin lymphoma (HL) patients treated in the modern era has not been well established. We conducted a retrospective study involving 202 advanced classical HL (cHL) patients treated from 1998.5 to 2015.7 to evaluate the impact of serum B2MG level on prognosis. Multivariate analysis showed that serum B2MG level >/= 2.5 mg/L was an independent predictor for freedom from progression (FFP) (P = 0.001), lymphoma-specific survival (P = 0.030) and overall survival (P = 0.034). The 5-year FFP of patients with serum B2MG level >/= 2.5 mg/L was 66.8%, compared with 89.7% in patients with B2MG level < 2.5 mg/L (P < 0.001). The traditionally used International Prognostic Score (IPS) remained prognostic for FFP (P = 0.013) but the predictive range narrowed, with 5-year FFP ranging from 90.9% to 62.3%. The 5-year FFP of the 44 patients with both IPS >/= 3 and serum B2MG >/= 2.5 mg/L was 50.7%, which was significantly worse than that of the 87 patients with only one of the two factors (81.9%, P < 0.001) or the 71 patients with both B2MG < 2.5 mg/L and IPS < 3 (91.1%, P < 0.001). The difference of FFP between the latter two groups was smaller but also significant (P = 0.038). In summary, our data suggest pretreatment serum B2MG level >/= 2.5 mg/L was an independent unfavorable prognostic factor in advanced cHL patients treated in the modern era. It improves IPS in predicting the outcomes as the combination of IPS and B2MG indentified a wider prognostic range than IPS alone with a sizable number of patients in different risk groups. FAU - Wang, Qin AU - Wang Q AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Qin, Yan AU - Qin Y AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Zhou, Shengyu AU - Zhou S AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - He, Xiaohui AU - He X AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Yang, Jianliang AU - Yang J AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Kang, Suyi AU - Kang S AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Liu, Peng AU - Liu P AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Yang, Sheng AU - Yang S AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Zhang, Changgong AU - Zhang C AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Gui, Lin AU - Gui L AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Sun, Yan AU - Sun Y AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. FAU - Shi, Yuankai AU - Shi Y AD - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (beta 2-Microglobulin) SB - IM MH - Adolescent MH - Adult MH - Age Factors MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Chemoradiotherapy MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Hodgkin Disease/*blood/*mortality/pathology/therapy MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Risk Factors MH - Sex Factors MH - Young Adult MH - beta 2-Microglobulin/*blood PMC - PMC5342156 OTO - NOTNLM OT - classical Hodgkin lymphoma OT - international prognostic score OT - prognosis OT - serum beta-2 macroglobulin COIS- CONFLICTS OF INTEREST All authors declare no conflicts of interest. EDAT- 2016/10/18 06:00 MHDA- 2018/02/24 06:00 PMCR- 2016/11/01 CRDT- 2016/10/18 06:00 PHST- 2016/09/06 00:00 [received] PHST- 2016/10/07 00:00 [accepted] PHST- 2016/10/18 06:00 [pubmed] PHST- 2018/02/24 06:00 [medline] PHST- 2016/10/18 06:00 [entrez] PHST- 2016/11/01 00:00 [pmc-release] AID - 12663 [pii] AID - 10.18632/oncotarget.12663 [doi] PST - ppublish SO - Oncotarget. 2016 Nov 1;7(44):72219-72228. doi: 10.18632/oncotarget.12663.